Introduction
The blood-brain barrier (BBB), located in the endothelium of brain capillaries, protects the central nervous system (CNS) from neurotoxins. A specialized network of microvessels, the BBB forms a chemical and structural barrier between the brain and circulatory system. Tight junction complexes restrict paracellular flow of solutes, and substrate-specific ATP-driven efflux transporters regulate levels of endogenous metabolites and xenobiotics (Begley, 2004) . When modified, the activity of these efflux transporters alters the permeability of the BBB (Miller, 2010) .
The most studied and highest expressed efflux transporter at the BBB is P-glycoprotein. Expressed luminally in brain endothelial cells, P-glycoprotein exports a vast range of substrates out of brain tissue and into the circulatory system, making it an essential part of neuroprotection and a redoubtable obstacle in drug delivery (Begley, 2004; . Some therapeutic strategies are designed to decrease P-glycoprotein activity to improve drug delivery into the CNS, while others attempt to increase P-glycoprotein activity to restrict the movement of toxins across the BBB and enhance CNS protection.
Specifically, in certain cases of CNS disease or injury, such as cerebral ischemia, traumatic brain injury, or subarachnoid hemorrhage, studies have proposed preserving the integrity of the BBB to protect against further cellular damage (Alfieri et al., 2011; Zhang et al., 2013) .
Even without clinical intervention, P-glycoprotein transport activity is dynamic. Studies show that P-glycoprotein transport increases or decreases in
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response to cellular injury, such as inflammation or oxidative stress (Seelbach et al., 2007; Miller et al., 2008; Chodobski et al., 2011; Wang et al., 2014) .
Increased P-glycoprotein activity has also been observed in animals with certain neurological and neuroinflammatory disorders, such as epilepsy and amyotropic lateral sclerosis (Brandt et al., 2006; Bauer et al., 2008; Milane et al., 2010; Jablonski et al., 2012) . Understanding the mechanisms that regulate Pglycoprotein and how basal P-glycoprotein is modulated will help the development of clinical targets for both enhanced neuroprotection and drug delivery.
Sphingolipids are signaling molecules that are endogenous to brain tissue and involved in inflammatory responses. However, despite observations that inflammation in brain tissue can alter BBB efflux transport, research regarding the involvement of sphingolipids at the BBB remains limited. Structurally, sphingolipids contain a sphingoid backbone acetylated at the N-terminal with a fatty acid chain specific to one of many ceramide species (Maceyka and Spiegel, 2004) . One of the most commonly studied sphingolipids is ceramide, which can be converted to many other species. The membrane-bound enzyme ceramide kinase (CERK) phosphorylates ceramide intracellularly to produce the proinflammatory molecule ceramide 1-phosphate (C1P) (Lamour and Chalfant, 2008) . Although the physiological role of C1P is not fully understood, in vitro studies suggest that C1P induces pro-inflammatory cascades, decreases apoptosis, increases cell survival, increases cell migration, and is released in
6 high levels from damaged cells (Granado et al., 2009; Arana et al., 2010; Gomez-Munoz et al., 2010 , Kim et al., 2013 .
Our lab has previously documented the ability of another sphinoglipid, sphingosine 1-phosphate (S1P), to regulate P-glycoprotein transport activity at the BBB (Cannon et al., 2012) . In this study, we investigated whether C1P could similarly regulate transport at the BBB, especially since its formative enzyme, CERK, is highly active in brain tissue (Van Overloop et al., 2005) . Our study explores the ability of C1P to modify P-glycoprotein activity at the BBB. In contrast to S1P, which decreases P-glycoprotein activity, we found that exposure of rat brain capillaries to C1P rapidly increases P-glycoprotein transport activity.
The effect is reversible, transporter-specific, and occurrs with no change to transporter protein expression. Further characterization revealed that the effect of C1P on P-glycoprotein transport activity is mediated via the cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE 2 ) signaling cascade. With these findings, we propose a model for C1P-mediated signaling that induces P-glycoprotein transport activity quickly and reversibly to render the BBB impermeable to toxins or drugs.
Materials and Methods

Chemicals
C18:1 ceramide 1-phosphate (d18:1/18:1) and sphingosine 1-phosphate (d18:1) were purchased from Avanti Polar Lipids (Alabaster, AL). Stock solution of C1P was prepared in 2:1 chloroform:methanol. [N-ε-(4-nitrobenzofurazan-7-yl)-D-
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8 mice and littermate controls on a 129B6F1 background were obtained from Dr.
Artiom Gruzdev at the National Institute of Environmental Health Sciences (Morham et al., 1995) . All animals were housed in temperature-controlled rooms under a 12h light-dark cycle with ad libitum access to food and water. Animals were euthanized by CO 2 inhalation followed by decapitation. For transport assays and immunohistochemistry, brain capillaries were harvested and used immediately; for western blots, capillaries were treated and stored at -80°C for further analysis.
Brain Capillary Isolation
The procedure for rat brain capillary isolation has been detailed previously (Miller et al., 2000; Hartz et al., 2004) . In summary, brains were stripped of their midbrain, meninges, choroid plexus, olfactory lobes, and white matter. The remaining brain tissue was homogenized in cold 1x PBS supplemented with glucose and sodium pyruvate (2.7mM KCL, 1.5 mM KH 2 PO 4 , 136.9mM NaCl, 8.1mM Na 2 HPO 4 ·7H 2 0, 1mM CaCl 2 ·2H 2 0, 1mM MgCl 2 ·6H 2 0, 5mM D-glucose, and 1mM sodium pyruvate). An equal volume of 30% Ficoll was added to the homogenate, and the solution was centrifuged at 6800rpm for 20min at 4°C to separate capillaries from the parenchyma. The resulting capillary pellet was resuspended in 1% BSA in PBS, passed over 30µm-mesh filters (pluriStrainer), and washed with PBS before immediate use.
Transport Assay
This article has not been copyedited and formatted. The final version may differ from this version. Details about transport activity assays using isolated brain capillaries may be found in previous studies Bauer et al., 2007) . Experiments in this study were performed at room temperature in chambered coverglass (Labtek) filled with 1x PBS. Isolated rat brain capillaries were allowed to adhere to the coverglass for at least 20min in plain 1x PBS, followed by incubation for 40min in a fluorescent substrate specific to one BBB efflux transporter: 2µM NBD-CSA for P-glycoprotein; 2µM Texas Red for MRP2; 2µM BODIPY prazosin for BCRP Wang et al., 2010) . Capillaries were treated with C1P plus NBD-CSA for a further 20min. In select cases, capillaries were pretreated for 40min with an inhibitor or antagonist plus NBD-CSA before exposure to C1P. For each experiment, one chamber contained 10µM PSC833, a specific P-glycoprotein inhibitor. Images of 10-20 capillaries were acquired per chamber using a Zeiss 510 confocal microscope with a 40x water-immersion objective.
Luminal fluorescence (as a measure of substrate accumulation) was analyzed via NIH Image J software. Specific P-glycoprotein activity was calculated as the difference between total luminal fluorescence and the fluorescence of capillaries exposed to PSC833.
Western Blotting
Whole capillary isolates were collected and assayed for protein concentration using the Bradford method. Protein aliquots were mixed with 4x loading buffer, added to a 4-12% Bis-Tris gel for electrophoresis, and transferred to an Immobilon-FL membrane. Membranes were blocked in Odyssey (Li-Cor) This article has not been copyedited and formatted. The final version may differ from this version. predicted band size 180kDal; secondary goat anti-mouse); for EP2, antiprostaglandin E receptor EP2 antibody (1/1000 dilution; predicted band size 40kDal; secondary goat anti-rabbit). As a loading control, membranes were also immunoblotted with β-actin (1/10,000 dilution; predicted band size 42kDa; secondary goat anti-mouse). Before imaging, membranes were washed in PBS with 0.1% Tween 20 and treated with corresponding secondary antibody IRDye 680RD for 1h. Imaging was performed with the Li-Cor Odyssey Infrared Imaging System.
Immunohistochemistry
Isolated capillaries were allowed to adhere to chambered coverglass, and were then fixed with 4% paraformaldehyde/0.2% glutaraldehyde for 15min. Chambers were washed with 1x PBS, permeabilized in 0.1% Triton X-100 (in PBS) for 30min, and blocked in 1% BSA (in PBS) for 30min. Capillaries were incubated with prostaglandin E Receptor EP2 antibody (rabbit; monoclonal; 1/500 dilution) overnight at 4°C. Negative control omitted primary antibody. Isotype control capillaries were incubated with rabbit monoclonal IgG primary antibody (1/25,000 dilution). Before imaging, capillaries were washed in 1x PBS, followed by exposure to Alexa Fluor-488-conjugated goat anti-mouse IgG for 1h at 37°C.
Imaging was performed by confocal microscopy using a Zeiss 510 microscope with a 40x water-immersion objective.
This article has not been copyedited and formatted. The final version may differ from this version. software. Differences between means were considered statistically significant when P < 0.05.
Results
C1P
Increases P-Glycoprotein Activity ex vivo. Our lab has previously established a confocal microscopy-based assay to measure the activity of transporters at the BBB in isolated rat brain capillaries (Miller et al., 2000; Hartz et al., 2004) . Specific transporter activity is determined by measuring the luminal accumulation of fluorescent substrates specific to a particular transporter. To assess the activity of P-glycoprotein in brain capillaries, we measured luminal accumulation of 2µM NBD-CSA at steady state (approximately 40min exposure).
To quantify specific P-glycoprotein activity, we subtracted the non-specific fluorescence of capillaries treated with 10µM PSC833, a potent P-glycoprotein inhibitor.
Using this method, we determined the effect of C1P exposure on BBB efflux transporter activity by exposing freshly isolated rat brain capillaries to 250nM C1P for 20min. Figure 1A shows representative confocal images of rat brain capillaries after 1h exposure to 2μM NBD-CSA (control), 250nM C1P This article has not been copyedited and formatted. The final version may differ from this version. (40min blank NBD-CSA followed by 20min C1P concurrently with NBD-CSA), or 10μM PSC833 (30min PSC833 pre-treatment, followed by 1h PSC833 concurrently with NBD-CSA). Figure 1B shows quantitatively that luminal accumulation of PSC833-treated capillaries decreased significantly by 50-60%.
This data is consistent with prior studies that show PSC833 maximally inhibits Pglycoprotein transport of NBD-CSA; any residual fluorescence after PSC833 treatment results from non-specific luminal entry ). (Fig.   1B ). PSC833-sensitive NBD-CSA luminal fluorescence in capillaries exposed to 250nM C1P was two-fold higher than control capillaries (Fig. 1C) . The PSC833-senstive luminal fluorescence of another P-glycoprotein substrate, rhodamine 123, was also found to increase two-fold after C1P exposure (Supplemental Figure 1 ). These data show that specific P-glycoprotein transport activity doubles in response to short-term 250nM C1P exposure.
Ceramide is Converted to C1P via CERK to Induce P-Glycoprotein. We tested whether ceramide, the intracellular precursor to C1P, could similarly affect P-glycoprotein activity. Exposing isolated rat brain capillaries to 250nM ceramide increased P-glycoprotein transport activity after 20min; however, compared with C1P, the effect was modest ( These results prompted us to analyze whether the delay in ceramidemediated P-glycoprotein induction resulted from intracellular conversion of ceramide to C1P. Given that ceramide kinase (CERK) converts ceramide into C1P, we treated isolated brain capillaries with a CERK inhibitor (50nM NVP-231) and measured P-glycoprotein activity. We found that CERK inhibition blocked the ability of ceramide to increase P-glycoprotein activity, indicating that ceramide must first be converted to C1P to induce P-glycoprotein transport activity (Fig.   2D ).
C1P Action is Rapid, Reversible and Transporter-Specific. To characterize the induction of P-glycoprotein activity caused by C1P, we exposed capillaries to concentrations of C1P ranging from 50nM to 250nM. After 20min, C1P increased P-glycoprotein activity in a concentration-dependent manner, with peak induction occurring between 100nM-250nM (Fig. 3A ). As such, we exposed capillaries to 250nM C1P in all subsequent experiments. To confirm that the changes in capillary fluorescence were biological, we analyzed the interaction between C1P
and NBD-CSA fluorescence in the absence of brain capillaries. An assessment of the baseline fluorescence of NBD-CSA with and without 250nM C1P confirmed that C1P does not chemically affect the intensity of NBD-CSA ( To investigate whether C1P affects any other efflux transporters at the BBB, we tested the effects of C1P exposure (250nM; 20min) on multidrug resistance protein 2 (MRP2) and breast cancer resistance protein (BCRP) in brain capillaries. Following exposure to C1P, we saw no changes in the luminal accumulations of the fluorescent substrates for these transporters: Texas Red for MRP2 and BODIPY Prasozin for BCRP. Quantitatively, we saw no change in the specific activity of these transporters (Fig. 3C ). Since C1P exposure elicited no changes to these transporters, we focused exclusively on P-glycoprotein for the remainder of our study.
In time course experiments, C1P induced P-glycoprotein transport in under 5min and sustained the induction for up to 90min, provided that C1P remained in the capillary treatment buffer (Fig. 3D ). When C1P was removed from the treatment buffer, P-glycoprotein transport activity returned to control levels in 1h (Fig. 3D ). These results suggest that C1P acts on P-glycoprotein in a rapid and reversible manner. Our lab has previously shown that translational events in brain capillaries require several hours to measurably affect transporter activity (Wang et al., 2014) . Hence, we hypothesized that C1P increased Pglycoprotein independently of transcription or translation. Western blots showed that neither 20min nor 4h exposure to C1P increased the total protein expression of P-glycoprotein in isolated rat brain capillaries (Fig. 4A, Fig. 4B and This article has not been copyedited and formatted. The final version may differ from this version. Figure 2 ). Further, we performed transport assays with capillaries that had been pre-treated with an inhibitor of either transcription (1μM actinomycin D) or translation (50μg/mL cycloheximide) prior to treatment with C1P. Neither inhibitor blocked C1P-mediated P-glycoprotein induction (Fig. 4C) .
Together, these data strongly suggest that C1P increases P-glycoprotein activity without increasing overall transporter protein expression. To explore an alternate mechanism of how P-glycoprotein is up-regulated, we pre-treated capillaries with 400nM brefeldin A, an inhibitor of vesicle formation that prevents intraceullar protein trafficking (Klausner et al., 1992) . While breldein A is certainly not specific for P-glycoprotein, it has previously been shown to prevent the trafficking of intracellular P-glycoprotein to the plasma membrane (Fu et al., 2004) . Our study found that pre-treatment with brefeldin A blocked C1P-mediated P-glycoprotein induction (Fig. 4D) . It is possible that exposure to C1P may lead to relocation of P-glycoprotein, causing increased P-glycoprotein activity at the BBB.
Alternatively, vesicle trafficking may be involved elsewhere in the C1P-initiated signaling cascade.
C1P Requires PLA2 and COX-2 Signaling. We sought to identify the signaling cascade through which C1P increases P-glycoprotein activity. Previous studies in cell lines indicate that C1P stimulates the release of arachidonic acid (AA) by activating cytosolic phospholipase A2 (PLA2) (Pettus et al., 2003 (Pettus et al., , 2004 Nakamura et al., 2006) . Furthermore, both AA and cyclooxygenase-2 (COX-2), the enzyme that converts AA into prostaglandins, have previously been associated with increased P-glycoprotein transport activity Zibell et al., 2009 ). As such, we investigated whether C1P depends on activation of an AA/COX-2-associated signaling cascade to alter P-glycoprotein activity.
We inhibited PLA2 by pre-treating capillaries with chlorpromazine (200nM; 40min), which blocked the ability of C1P to increase P-glycoprotein activity (Fig.   5A ). Next, we blocked COX-2 with two selective inhibitors: celecoxib (100nM; 40min) and NS-398 (5μM; 40min), which similarly blocked the action of C1P ( Fig.   5B and Fig. 5C ). To futher confirm that COX-2 was required for C1P-mediated Pglycoprotein induction, we performed transport assays using COX-2-deficient mice. Figure 5D shows that C1P treatment on wild-type mice brain capillaries resulted in a two-fold fluorescence increase of P-glycoprotein activity comparable to the increases observed in wild-type rat brain capillaries. C1P exposure in brain capillaries isolated from COX-2-deficient mice produced no change in the luminal accumulation of NBD-CSA (Fig. 5D ). These results indicate that COX-2 is necessary for C1P to increase P-glycoprotein activity.
C1P Pathway Involves PGE 2 Receptor. Previous research in cell lines has
proposed the existence of a yet-unidentified G-protein coupled C1P-specific receptor (Granado et al., 2008) . In our study, blocking G i , G o and G s activation with a G-protein antagonist peptide prevented C1P from inducing P-glycoprotein activity (Fig. 6A) . However, since no C1P-specific receptor has yet been identified in brain capillaries, we sought to investigate alternative explanations for This article has not been copyedited and formatted. The final version may differ from this version. The enzyme COX-2 produces prostaglandin H 2 from AA, which is then converted to various prostaglandins, including prostaglandin E2 (PGE 2 ). PGE 2 is transported extracellularly by multidrug resistance protein 4 (MRP4) where it activates four G-protein coupled receptors: EP1, EP2, EP3 and EP4 (Coleman et al., 1994; Reid et al., 2003) . Research has previously associated PGE 2 production with S1P and C1P (Pettus et al., 2005) , and EP1 and EP2 receptors have been associated with BBB health and maintenance (McCullough et al., 2004; Pekcec et al., 2009 ). More specifically, several studies have implicated the EP2 receptor in inflammation, cell migration, proliferation, apoptosis, and angiogenesis -processes associated with C1P or BBB transport (Sung et al., 2005; Kamiyama et al., 2006; Liang et al., 2008; Jiang and Dingledine, 2013) .
We tested whether C1P signaled through any PGE 2 receptors to increase P-glycoprotein activity. Firstly, we targeted MRP4, the transporter that moves PGE 2 from the intracellular to the extracellular matrix (Reid et al., 2003) . Pretreatment with an inhibitor of MRP4, ceefourin (1μM; 40min), blocked the ability of C1P to induce P-glycoprotein activity (Fig. 6B) . Secondly, we focused on the EP1 and EP2 receptors. Considerable levels of EP1 have already been noted in brain capillary membranes (Pekcec et al., 2009) . To test whether EP2 is similarly present in brain capillaries, we performed western blotting on cytosolic and membrane lysate fractons from isolated capillaries, using anti-prostaglandin E receptor EP2 antibody (rabbit, monoclonal, 1/1000 dilution). EP2 protein was found to be expressed in both fractions (Fig. 6C) . Immunohistochemistry analysis confirmed that the EP2 receptor is expressed in rat brain capillaries and is most abundantly localized in the luminal membrane ( Fig. 6D and Fig. 6E ).
Transport assays revealed that pre-treatment with AH-6809 (835nM; 40min), a dual-antagonist for EP1 and EP2, completely inhibited the ability of C1P to alter P-glycoprotein activity in brain capillaries (Fig. 6F) . Pre-treatment with an EP1-specific antagonist, SC51089 (1μM; 40min), only partially inhibited the action of C1P without also lowering control activity of P-glycoprotein (Fig.   6G ). On the other hand, pre-treating with an EP2-specific antagonist, PF-04418949 (10nM and 100nM; 40min), blocked C1P action in a concentrationdependent manner, with the highest concentration completely abolishing C1P action without affecting control P-glycoprotein activity (Fig. 6H) . In all, these data suggest that C1P requires the action of PLA2, COX-2, PGE 2, and EP2 to increase P-glycoprotein activity. To a lesser extent, C1P may also require the action of EP1. Figure 7 shows a complete working model of this proposed pathway.
Discussion
Efflux transporters at the BBB remain an obstacle to CNS pharmacotherapy yet are an effective form of neuroprotection. Understanding the biological mechanisms that regulate basal activity of these transporters is critical in developing clinical targets for improved drug delivery to the brain or increasing CNS protection in cases of cellular injury or stress (Miller, 2010) . In this study, we demonstrate that short-term exposure to eighteen-carbon C1P, an endogenous sphingolipid in brain tissue, increases P-glycoprotein transport activity in isolated rat and mouse brain capillaries. Furthermore, we show the requirement for signaling through PLA2, COX-2 and PGE 2. Given that C1P acts rapidly and is highly expressed in brain tissue, we speculate that C1P levels regulate a signaling pathway that rapidly increases basal activity of P-glycoprotein, regulating minute-by-minute transport at the BBB.
Exposure to long-chain (eighteen-carbon) ceramide, the precursor for C1P, increases P-glycoprotein activity similarly to eighteen-carbon C1P.
However, unlike C1P, ceramide requires the activity of CERK, the enzyme that converts ceramide into C1P. Furthermore, ceramide requires considerably more time than C1P to increase P-glycoprotein activity. Both observations lead us to speculate that exogenous ceramide must first undergo conversion into C1P before altering P-glycoprotein activity and that ceramide alone has no measurable, short-term effect on P-glycoprotein. Prior research shows that CERK is highly active in brain tissue and acts optimally on ceramides with twelve-acyl carbon chains or longer (Van Overloop et al., 2005; Wijesinghe et al., 2005) . Unsurprisingly, the most abundant C1P species found in brain tissue contain sixteen-carbon chains or longer (Yamashita et al., 2016) . Therefore, CERK activity may modulate basal P-glycoprotein transport activity at the BBB by converting long-chain ceramide species into C1P.
Given that drug efflux pumps like P-glycoprotein contribute substantially to multidrug resistance in certain diseases, these findings point to a potential role for C1P and CERK in drug resistance. Down-regulation of ceramide, an important mediator of apoptosis, has been associated with poor prognosis and multidrug resistance in tumors, possibly as a result of dysfunctional metabolism into other sphingolipid species (Senchenkov et al., 2001; Koybasi et al., 2004 ).
As such, enzymes that metabolize ceramide, such as CERK, could be targeted for tumor therapy (Reynolds et al., 2003; Payne et al., 2014) . In light of our findings, the phosphorylation of ceramide by CERK should be investigated in cases of multidrug resistance to determine whether such resistance results from elevations in P-glycoprotein activity caused by C1P.
Our experiments using fluorescent substrates for other transporters suggest that C1P acts selectively on P-glycoprotein. Following C1P treatment, we observed no changes in the accumulation of luminal fluorescence of capillaries incubated with Texas Red (substrate for MRP2) or BODIPY Prazosin (substrate for BCRP). These results indicate that i) C1P does not affect the transport activity of MRP2 or BCRP and ii) the structural integrity of endothelial tight junctions remains unaffected in capillaries exposed to C1P. In the scope of our study, C1P seems to act exclusively on the transport activity of Pglycoprotein.
In time course experiments, we determined that the effect of C1P on Pglycoprotein occurs in approximately 5-15min and reverses fully within 1h after C1P is removed from capillaries. Previously, our lab has shown that another sphingolipid, S1P, decreases P-glycoprotein activity in a comparably rapid and reversible manner (Cannon et al., 2012) . Such immediate action suggests that endogenous C1P, S1P, and possibly other sphingolipids in brain tissue regulate minute-by-minute activity of P-glycoprotein at the BBB.
Our study also indicates that C1P acts through signaling and does not increase the overall protein expression of P-glycoprotein in rat brain capillaries.
Western blots revealed that the total protein expression of P-glycoprotein is not induced following treatment with C1P, and transport assays confirmed that C1P does not require the processes of transcription or translation in order to affect Pglycoprotein transport activity. To our knowledge, this is the first time a molecule has been shown to increase P-glycoprotein activity with no change to overall transporter protein expression. This may be an important component of basal Pglycoprotein activity regulation. In cases when the BBB must be rendered immediately impermeable to environmental toxins or harmful xenobiotics, C1P could produce a rapid increase of efflux from the BBB, resulting in greater neuroprotection.
To begin elucidating a possible mechanism that is independent of protein expression, we found that inhibiting protein trafficking blocks the ability of C1P to increase P-glycoprotein activity. P-glycoprotein has been shown to exist not only at the plasma membrane but also within intracellular compartments, including the endoplasmic reticulum, Golgi, and cytoplasmic vesicles (Bendayan et al., 2006; Fu and Arias, 2012) . Some studies suggest that accumulation of intracellular Pglycoprotein caused by inhibition of protein trafficking can interfere with Pglycoprotein function (Fu et al., 2004; McCaffrey et al., 2012) . Our results suggest that C1P exposure may promote trafficking of intracellular P-glycoprotein to the capillary membrane, which could increase transport activity of Pglycoprotein at the BBB without increasing overall transporter protein expression.
However, since other components in the C1P signaling cascade may also be subject to trafficking, this mechanism must be explored in future studies with less general inhibitors of protein traffic.
Using specific signaling inhibitors, immunohistochemistry analysis, and COX-2-deficient mice, we have characterized the involvement of the PLA2/COX-2/PGE 2 inflammatory signaling pathway in C1P-mediated P-glycoprotein induction. Previous cell models show that C1P targets and activates cytosolic PLA2 (Pettus et al., 2003; Nakamura et al., 2006) , which subsequently stimulates a high release of AA (Pettus et al., 2004) . Downstream in this pathway, COX-2 converts AA into prostaglandins. Studies have implicated COX-2 in Pglycoprotein up-regulation Zibell et al., 2009 ). Together, these findings led us to speculate that a connection exists between C1P and COX-2-mediated P-glycoprotein induction. Indeed, our results showed that COX-2 activity is necessary for C1P to increase the activity of P-glycoprotein in isolated rat and mouse brain capillaries.
We further identified that EP2, a G-protein coupled receptor for PGE 2 , is involved in the induction of P-glycoprotein caused by C1P. In cell lines, C1P has been shown to increase PGE 2 production, even at concentrations as low as 300nM (Pettus et al., 2005) . Additional studies have proposed the involvement of G-protein coupled receptors in C1P signaling (Granado et al., 2008) . While our study did not identify any C1P-specific receptors in brain capillaries, we found Previous studies associate EP receptors with the BBB (McCullough et al., 2004; Pekcec et al., 2009; Jiang and Dingeldine, 2013) . EP2, in particular, shares biological characteristics with C1P; both EP2 and C1P have been implicated with decreased apoptosis, increased angiogenesis, and the promotion of inflammatory responses through COX-2 (Sung et al., 2005; Kamiyama et al., 2006; Liang et al., 2008; Kim et al., 2013; Rivera et al., 2015) . Our results show that EP2 exists almost exclusively on the luminal membrane of rat brain capillaries, suggesting that in our model PGE 2 activates its receptor in the capillary lumen. Signaling components downstream of PGE 2 should be identified to determine the full pathway through which C1P increases P-glycoprotein activity.
Drug resistance in disorders such as brain cancer, epilepsy, and depression show associations with higher activity of efflux transporters at the BBB, including P-glycoprotein (Loscher and Potschka, 2005; Brandt et al., 2006) . It is not uncommon for such diseases to also exhibit increased levels of the enzymes involved in C1P production, such as CERK and sphingomyelinase D. of sphingomyelinase D (Kornhuber et al., 2005) . Given the results of our study, future work should explore the associations between C1P-mediated Pglycoprotein induction and drug resistance associated with precursors of C1P.
Drug resistance in certain diseases might be linked with C1P-mediated upregulation of transporters that restrict drug access to the CNS.
On the other hand, P-glycoprotein is critical for brain homeostasis and limits the passage of harmful metabolites and xenobiotics into the CNS. Studies have shown that inflammation can change the activity of P-glycoprotein (Bauer et al., 2007; Chodobski 2011) , and some speculate that up-regulation of P-glycoprotein in response to inflammation may actually provide neuroprotection (Seelbach et al., 2007; Alfieri et al., 2011) . Over recent years, targeting sphingolipids has become an attractive clinical possibility for the treatment of various health conditions; for example, studies propose targeting C1P and CERK for tissue regeneration and the treatment of inflammatory diseases, cancer, and other conditions (Zeidan and Hannun, 2007; Granado et al., 2009; Arana et al., 2010; Gomez-Munoz et al., 2010; Kim et al., 2013; Maceyka and Spiegel, 2014; Pastukhov et al., 2014; Baudiss et al., 2016) . Given our results, the neuroprotective functions of C1P, CERK, and other sphingolipids should be considered in these cases. While inhibition of C1P or CERK might be an effective therapeutic strategy certain cases, it might also have the potential to lower CNS protection against further cellular harm.
From our results, we propose that endogenous production of C1P via CERK in brain tissue increases the basal activity of P-glycoprotein and contributes to general neuroprotection in healthy brains. In cases of cellular injury or stress, it is possible that increases in C1P would protect against additional cellular damage. Conversely, in disease states wherein the levels of C1P and CERK increase, the activation of the PLA2/COX-2/PGE 2 pathway may contribute to drug resistance. As such, the ability of C1P and CERK to restrict BBB transport could either be targeted for enhanced drug delivery or exploited for neuroprotection. Also important is the potential for enzymatic interconversion of the sphingolipids (C1P and S1P) and their ability to rapidly alter P-glycoprotein activity in opposite directions. Controlling the balance of C1P and S1P cellular levels would provide a mechanism for dynamic regulation of P-glycoprotein transport activity at the BBB. In all, our data support that C1P is an important regulator of P-glycoprotein activity and has the potential to be a versatile molecule for clinical manipulation. with a COX-2 inhibitor (100nM Celecoxib) blocks the increases in P-glycoprotein activity caused by C1P treatment. C) Another COX-2 inhibitor (5μM similarly blocks the increases in P-glycoprotein activity caused by C1P treatment.
D)
Exposing COX-2 deficient mouse brain capillaries to 250nM C1P for 20min resulted in no induction of P-glycoprotein activity. Wild-type mouse brain capillaries exposed to 250nM C1P for 20min exhibit an increase in P-glycoprotein activity comparable to that of wild-type rat brain capillaries. Shown are mean ± SEM for 10-20 capillaries from single preparation (pooled brains from 3-5 rats or 4-6 mice). ***P<0.001, ****P<0.0001, significantly higher than control. This article has not been copyedited and formatted. The final version may differ from this version. 
